

File 5:Biosis Previews(R) 1969-2003/Sep W2
(c) 2003 BIOSIS

File 6:NTIS 1964-2003/Sep W4
(c) 2003 NTIS, Intl Cpyrght All Rights Res

File 8:Ei Compendex(R) 1970-2003/Sep W2
(c) 2003 Elsevier Eng. Info. Inc.

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Sep W3
(c) 2003 Inst for Sci Info

File 65:Inside Conferences 1993-2003/Sep W3
(c) 2003 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2003/Sep W3
(c) 2003 Elsevier Science B.V.

File 73:EMBASE 1974-2003/Sep W3
(c) 2003 Elsevier Science B.V.

File 94:JICST-EPlus 1985-2003/Sep W3
(c) 2003 Japan Science and Tech Corp (JST)

File 98:General Sci Abs/Full-Text 1984-2003/Aug
(c) 2003 The HW Wilson Co.

File 99:Wilson Appl. Sci & Tech Abs 1983-2003/Aug
(c) 2003 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2003/Sep W3
(c) 2003 NewsRx

File 143:Biol. & Agric. Index 1983-2003/Aug
(c) 2003 The HW Wilson Co

File 144:Pascal 1973-2003/Sep W2
(c) 2003 INIST/CNRS

File 155:MEDLINE(R) 1966-2003/Sep W4
(c) format only 2003 The Dialog Corp.

File 172:EMBASE Alert 2003/Sep W3
(c) 2003 Elsevier Science B.V.

File 266:FEDRIP 2003/Aug
Comp & dist by NTIS, Intl Copyright All Rights Res

File 315:ChemEng & Biotec Abs 1970-2003/Aug
(c) 2003 DECHEMA

File 357:Derwent Biotech Res. 1982-2003/Oct W1
(c) 2003 Thomson Derwent & ISI

File 358:Current BioTech Abs 1983-2003/Aug
(c) 2003 DECHEMA

File 369:New Scientist 1994-2003/Sep W3
(c) 2003 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3
(c) 1999 AAAS

File 399:CA SEARCH(R) 1967-2003/UD=13913
(c) 2003 American Chemical Society

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info

File 40:Enviroline(R) 1975-2003/Aug

File 50:CAB Abstracts 1972-2003/Aug
(c) 2003 CAB International

File 103:Energy SciTec 1974-2003/Sep B1
(c) 2003 Contains copyrighted material

File 156:ToxFile 1965-2003/Sep W3
(c) format only 2003 The Dialog Corporation

File 162:Global Health 1983-2003/Aug
(c) 2003 CAB International

File 305:Analytical Abstracts 1980-2003/Sep W1
(c) 2003 Royal Soc Chemistry

File 35:Dissertation Abs Online 1861-2003/Aug
(c) 2003 ProQuest Info&Learning

File 48:SPORTDiscus 1962-2003/Sep
(c) 2003 Sport Information Resource Centre

File 91:MANTIS(TM) 1880-2002/Dec
2003 (c) Action Potential

File 149:TGG Health&Wellness DB(SM) 1976-2003/Sep W2
(c) 2003 The Gale Group

File 159:Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog Corporation

File 164:Allied & Complementary Medicine 1984-2003/Sep

(c) 2003 BLHCIS

File 444:New England Journal of Med. 1985-2003/Sep W4

(c) 2003 Mass. Med. Soc.

File 467:ExtraMED(tm) 2000/Dec

(c) 2001 Informania Ltd.

Set	Items	Description
S1	4367	INOSINE (S) GUANOSINE
S2	0	INOSINE (S) (BASE PAIR?)
S3	514	INOSINE (S) CYTOSINE
S4	0	S3 AND (BASE WITH PAIR?)
S5	13	S3 (S) HYBRIDIZ?
S6	12	RD (unique items)
S7	0	INOSINE (S) (PYRROLO PYRIMIDINE)
S8	4	INOSINE AND (PYRROLO (W) PYRIMIDINE)
S9	4	RD (unique items)

>>>KWIC option is not available in file(s): 399

File 5:Biosis Previews(R) 1969-2003/Sep W2
(c) 2003 BIOSIS
File 6:NTIS 1964-2003/Sep W4
(c) 2003 NTIS, Intl Cpyrght All Rights Res
File 8:Ei Compendex(R) 1970-2003/Sep W2
(c) 2003 Elsevier Eng. Info. Inc.
File 34:SciSearch(R) Cited Ref Sci 1990-2003/Sep W3
(c) 2003 Inst for Sci Info
File 65:Inside Conferences 1993-2003/Sep W3
(c) 2003 BLDSC all rts. reserv.
File 71:ELSEVIER ·BIOBASE 1994-2003/Sep W3
(c) 2003 Elsevier Science B.V.
File 73:EMBASE 1974-2003/Sep W3
(c) 2003 Elsevier Science B.V.
File 94:JICST-EPlus 1985-2003/Sep W3
(c) 2003 Japan Science and Tech Corp (JST)
File 98:General Sci Abs/Full-Text 1984-2003/Aug
(c) 2003 The HW Wilson Co.
File 99:Wilson Appl. Sci & Tech Abs 1983-2003/Aug
(c) 2003 The HW Wilson Co.
File 135:NewsRx Weekly Reports 1995-2003/Sep W3
(c) 2003 NewsRx

***File 135: New newsletters are now added. See Help News135 for the complete list of newsletters.**

File 143:Biol. & Agric. Index 1983-2003/Aug
(c) 2003 The HW Wilson Co
File 144:Pascal 1973-2003/Sep W2
(c) 2003 INIST/CNRS
File 155:MEDLINE(R) 1966-2003/Sep W4
(c) format only 2003 The Dialog Corp.

***File 155: Medline has been reloaded and accession numbers have changed. Please see HELP NEWS 155.**

File 172:EMBASE Alert 2003/Sep W3
(c) 2003 Elsevier Science B.V.
File 266:FEDRIP 2003/Aug
Comp & dist by NTIS, Intl Copyright All Rights Res
File 315:ChemEng & Biotec Abs 1970-2003/Aug
(c) 2003 DEchema
File 357:Derwent Biotech Res. 1982-2003/Oct W1
(c) 2003 Thomson Derwent & ISI

***File 357: File is now current. See HELP NEWS 357.**

Alert feature enhanced for multiple files, etc. See HELP ALERT.

File 358:Current BioTech Abs 1983-2003/Aug
(c) 2003 DEchema
File 369:New Scientist 1994-2003/Sep W3
(c) 2003 Reed Business Information Ltd.
File 370:Science 1996-1999/Jul W3
(c) 1999 AAAS

***File 370: This file is closed (no updates). Use File 47 for more current information.**

File 399:CA SEARCH(R) 1967-2003/UD=13913
(c) 2003 American Chemical Society

***File 399: Use is subject to the terms of your user/customer agreement.**
Alert feature enhanced for multiple files, etc. See HELP ALERT.

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info
File 40:Enviroline(R) 1975-2003/Aug
File 50:CAB Abstracts 1972-2003/Aug
(c) 2003 CAB International

***File 50: Truncating CC codes is recommended for full retrieval.**
See Help News50 for details.

File 103:Energy SciTec 1974-2003/Sep B1
(c) 2003 Contains copyrighted material

***File 103: For access restrictions see Help Restrict.**
File 156:ToxFile 1965-2003/Sep W3
(c) format only 2003 The Dialog Corporation

***File 156: ToxFile has been reloaded. Accession numbers**

have changed. Please see HELP NEWS 156 for details.

File 162:Global Health 1983-2003/Aug
(c) 2003 CAB International

***File 162: Effective May 1, name changes from CAB Health to Global Health.**

File 305:Analytical Abstracts 1980-2003/Sep W1
(c) 2003 Royal Soc Chemistry

***File 305: Alert feature enhanced for multiple files, duplicate removal, customized scheduling. See HELP ALERT.**

File 35:Dissertation Abs Online 1861-2003/Aug
(c) 2003 ProQuest Info&Learning

File 48:SPORTDiscus 1962-2003/Sep
(c) 2003 Sport Information Resource Centre

File 91:MANTIS(TM) 1880-2002/Dec
2003 (c) Action Potential

File 149:TGG Health&Wellness DB(SM) 1976-2003/Sep W2
(c) 2003 The Gale Group

File 159:Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog Corporation

***File 159: Cancerlit ceases updating with immediate effect.**

Please see HELP NEWS.

File 164:Allied & Complementary Medicine 1984-2003/Sep
(c) 2003 BLHCIS

File 444:New England Journal of Med. 1985-2003/Sep W4
(c) 2003 Mass. Med. Soc.

File 467:ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd.

***File 467: For information about updating status please see Help News467.**

Set	Items	Description
---	---	---
?s	inosine (s)	guanosine
	32995	INOSINE
	126623	GUANOSINE
S1	4367	INOSINE (S) GUANOSINE
?s	inosine (s) (base pair?)	
	32995	INOSINE
	14414	BASE PAIR?
S2	0	INOSINE (S) (BASE PAIR?)
?s	inosine (s) cytosine	
	32995	INOSINE
	110766	CYTOSINE
S3	514	INOSINE (S) CYTOSINE
?s	s3 and (base with pair?)	
	514	S3
	0	BASE WITH PAIR?
S4	0	S3 AND (BASE WITH PAIR?)
?s	s3 (s) hybridiz?	
	514	S3
	909228	HYBRIDIZ?
S5	13	S3 (S) HYBRIDIZ?

?rd

...completed examining records

S6 12 RD (unique items)

?show files;ds;td;3,k/all

File 5:Biosis Previews(R) 1969-2003/Sep W2
(c) 2003 BIOSIS

File 6:NTIS 1964-2003/Sep W4
(c) 2003 NTIS, Intl Cpyrght All Rights Res

File 8:Ei Compendex(R) 1970-2003/Sep W2
(c) 2003 Elsevier Eng. Info. Inc.

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Sep W3
(c) 2003 Inst for Sci Info

File 65:Inside Conferences 1993-2003/Sep W3
(c) 2003 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2003/Sep W3
(c) 2003 Elsevier Science B.V.

File 73:EMBASE 1974-2003/Sep W3
 (c) 2003 Elsevier Science B.V.
 File 94:JICST-EPlus 1985-2003/Sep W3
 (c) 2003 Japan Science and Tech Corp (JST)
 File 98:General Sci Abs/Full-Text 1984-2003/Aug
 (c) 2003 The HW Wilson Co.
 File 99:Wilson Appl. Sci & Tech Abs 1983-2003/Aug
 (c) 2003 The HW Wilson Co.
 File 135:NewsRx Weekly Reports 1995-2003/Sep W3
 (c) 2003 NewsRx
 File 143:Biol. & Agric. Index 1983-2003/Aug
 (c) 2003 The HW Wilson Co
 File 144:Pascal 1973-2003/Sep W2
 (c) 2003 INIST/CNRS
 File 155:MEDLINE(R) 1966-2003/Sep W4
 (c) format only 2003 The Dialog Corp.
 File 172:EMBASE Alert 2003/Sep W3
 (c) 2003 Elsevier Science B.V.
 File 266:FEDRIP 2003/Aug
 Comp & dist by NTIS, Intl Copyright All Rights Res
 File 315:ChemEng & Biotec Abs 1970-2003/Aug
 (c) 2003 DECHEMA
 File 357:Derwent Biotech Res. 1982-2003/Oct W1
 (c) 2003 Thomson Derwent & ISI
 File 358:Current BioTech Abs 1983-2003/Aug
 (c) 2003 DECHEMA
 File 369:New Scientist 1994-2003/Sep W3
 (c) 2003 Reed Business Information Ltd.
 File 370:Science 1996-1999/Jul W3
 (c) 1999 AAAS
 File 399:CA SEARCH(R) 1967-2003/UD=13913
 (c) 2003 American Chemical Society
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 1998 Inst for Sci Info
 File 40:Enviroline(R) 1975-2003/Aug
 File 50:CAB Abstracts 1972-2003/Aug
 (c) 2003 CAB International
 File 103:Energy SciTec 1974-2003/Sep B1
 (c) 2003 Contains copyrighted material
 File 156:ToxFile 1965-2003/Sep W3
 (c) format only 2003 The Dialog Corporation
 File 162:Global Health 1983-2003/Aug
 (c) 2003 CAB International
 File 305:Analytical Abstracts 1980-2003/Sep W1
 (c) 2003 Royal Soc Chemistry
 File 35:Dissertation Abs Online 1861-2003/Aug
 (c) 2003 ProQuest Info&Learning
 File 48:SPORTDiscus 1962-2003/Sep
 (c) 2003 Sport Information Resource Centre
 File 91:MANTIS(TM) 1880-2002/Dec
 2003. (c) Action Potential
 File 149:TGG Health&Wellness DB(SM) 1976-2003/Sep W2
 (c) 2003 The Gale Group
 File 159:Cancerlit 1975-2002/Oct
 (c) format only 2002 Dialog Corporation
 File 164:Allied & Complementary Medicine 1984-2003/Sep
 (c) 2003 BLHCIS
 File 444:New England Journal of Med. 1985-2003/Sep W4
 (c) 2003 Mass. Med. Soc.
 File 467:ExtraMED(tm) 2000/Dec
 (c) 2001 Informania Ltd.

Set	Items	Description
S1	4367	INOSINE (S) GUANOSINE
S2	0	INOSINE (S) (BASE PAIR?)
S3	514	INOSINE (S) CYTOSINE
S4	0	S3 AND (BASE WITH PAIR?)

S5 13 S3 (S) HYBRIDIZ?
S6 12 RD (unique items)
>>>KWIC option is not available in file(s): 399

6/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

06080959 BIOSIS NO.: 000085044108

THE INFLUENCE OF EXOCYCLIC SUBSTITUENTS OF PURINE BASES ON DNA CURVATURE
AUTHOR: DIEKMANN S; VON KITZING E; MCLAUGHLIN L; OTT J; ECKSTEIN F
AUTHOR ADDRESS: MAX-PLANCK-INST. FUER BIOPHYSIKALISCHE CHEMIE, AM FASSBERG,
D-3400 GOETTINGEN, W. GER.

JOURNAL: PROC NATL ACAD SCI U S A 84 (23). 1987. 8257-8261. 1987

FULL JOURNAL NAME: Proceedings of the National Academy of Sciences of the
United States of America

CODEN: PNASA

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

...ABSTRACT: or deoxycytidine stretches, respectively, of the general form 5'-d(GGGCAARAAC).cntdot.5'-d(CCCGTTYTTG), where R represents the bases adenine (A), hypoxanthine (base of *inosine* nucleoside, I) purine...

...R) and where Y represents the pyrimidine bases thymine (T) or *cytosine* (C), have been chemically synthesized. After *hybridization* of complementary fragments, they were ligated to form multimers and analyzed by polyacrylamide gel electrophoresis. Anomalous gel migration was observed for the sequences 5'-d...

6/3,K/2 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0319688 DBR Accession No.: 2003-20828 PATENT

Simultaneously sequencing multiple nucleic acid targets using modified primers and sequencing conditions, useful in diagnosis of disease or disorder - DNA primer for simultaneous DNA sequencing

AUTHOR: ESHLEMAN J R; MURPHY K M

PATENT ASSIGNEE: UNIV JOHNS HOPKINS 2003

PATENT NUMBER: WO 200356030 PATENT DATE: 20030710 WPI ACCESSION NO.: 2003-569457 (200353)

PRIORITY APPLIC. NO.: US 361125 APPLIC. DATE: 20020301

NATIONAL APPLIC. NO.: WO 2002US36075 APPLIC. DATE: 20021108

LANGUAGE: English

...ABSTRACT: single nucleic acid molecule or multiple nucleic acid molecules, comprising: (a) providing a single or multiple target nucleic acid primer molecules, where each primer molecule *hybridizes* to a distinct area of the target nucleic acid molecules; and (b) amplifying the target nucleic acid molecules, where deoxyribonucleosides triphosphates are present during the...

... coding DNA. The nucleic acid targets are from the same or different genes or their fragments. The forward and reverse nucleic acid primer molecules each *hybridizes* to a distinct area of the target nucleic acid molecules and the primers are of varying lengths, modifications, and sizes. The primers are present at...

... by biotinylation, blocking group, use of branched primers and the like. The primers are modified by conjugate molecules to further increase the binding affinity and *hybridization* rate of these oligonucleotides to a target. The conjugate molecules are selected from cationic amines, intercalating dyes, antibiotics, proteins, peptide fragments, or metal ion complexes. The primers are modified to increase avidity of binding and/or *hybridization* rates between a primer and its target nucleic

acid. The primers are comprised of 2' modifications to a ribofaransyl ring of a primer or any...

... of longer length and modified. The modified reverse primers comprise non-template nucleic acids. One or more modified reverse or forward primers comprise a polythymidine, *polycytosine* , polyguanine, polyadenine, polyuracil, *polyinosine* , or other nucleic acid or non-nucleic acid containing tail. The primers are used at unequal molar ratios to perform combined amplification and sequencing. The...

6/3,K/3 (Item 2 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0316554 DBR Accession No.: 2003-17694 PATENT

New pharmaceutical composition with angiopoietin-like 1 and angiopoietin-like 2 nucleic acids and proteins, useful in diagnosing and/or treating blood-related disorders and defects in vasculature, including leukemia and anemia - lipid or virus vector-mediated gene transfer and expression in bacterium, yeast, insect, teleost, amphibian or mammal cell for expression profiling for disease diagnosis and gene therapy

AUTHOR: ESGUERRA C V

PATENT ASSIGNEE: MERMAID PHARM GMBH 2003

PATENT NUMBER: EP 1308511 PATENT DATE: 20030507 WPI ACCESSION NO.: 2003-450962 (200343)

PRIORITY APPLIC. NO.: US 335362 APPLIC. DATE: 20011031

NATIONAL APPLIC. NO.: EP 200221286 APPLIC. DATE: 20020919

LANGUAGE: English

...ABSTRACT: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethyiaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, *inosine* , N6-isopentenyladenine, 1-methylguanine, 1-*methylinosine* , 2,2-dimethylguanine 2-methyladenine, 2-methylguanine 3-*methylcytosine* , 5-methylicytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 51-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-*thiocytosine* , 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-Soxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3...

... of hemoglobin staining is the direct result of an alteration in hematopoiesis, erythropoiesis and/or angiogenesis due to ANPTL1 gene knockdown, whole mount *in situ* *hybridization* analysis was performed on treated embryos using tissue-specific genetic markers for blood progenitors and early vasculature. The results showed that ANGPTL1 may not play...

6/3,K/4 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0313157 DBR Accession No.: 2003-14297 PATENT

Assaying target nucleic acids, involves using unstructured nucleic acids which have a reduced likelihood of hybridization with each other while maintaining their ability to hybridize with other nucleic acids - DNA detection, sorting, tracking and characterization using DNA probe and DNA array

AUTHOR: YAKHINI Z H; SAMPSON J R; MYERSON J

PATENT ASSIGNEE: AGILENT TECHNOLOGIES INC 2003

PATENT NUMBER: EP 1288313 PATENT DATE: 20030305 WPI ACCESSION NO.: 2003-344763 (200333)

PRIORITY APPLIC. NO.: US 938937 APPLIC. DATE: 20010824
NATIONAL APPLIC. NO.: EP 2002255908 APPLIC. DATE: 20020823
LANGUAGE: English

ABSTRACT: DERWENT ABSTRACT: NOVELTY - Assaying target nucleic acids (NAs), comprising using first number (N1) of NAs having unstructured nucleotides (UNAs) that have reduced ability to *hybridize* to other complementary NAs having UNAs, and second number (N2) of NAs having first and second regions (R1,R2), is new. R1 is complementary to and *hybridizes* to N1, and R2 has UNAs that minimize/eliminate undesired cross *hybridization* between R2 and N1. DETAILED DESCRIPTION - Assaying (M) target nucleic acid molecules by tagging and sorting the target molecules, comprising: (a) providing a first number...

... second nucleic acid of the second number comprise unstructured nucleotides so that the second region of each second nucleic acid has a reduced ability to *hybridize* to a first probe of the first number having a complementary sequence without reducing the ability of the second region of each second nucleic acid to *hybridize* to a complementary nucleic acid molecule in a biological sample; (c) providing a biological sample containing nucleic acids to be analyzed; (d) contacting the biological sample with the second number of probes under conditions that permit *hybridization* of complementary sequences between the nucleic acid molecules in the sample and the second region of second nucleic acids of the second number; (e) contacting the second number of probes with the first number of probes under conditions that permit *hybridization* of complementary sequences between the first region of a second probe of the second number and the first probes in the first number; (f) detecting nucleic acids in the biological sample that have *hybridized* to a nucleic acid of the second number; and (g) determining the sequence of the nucleic acid in the biological sample that has *hybridized* to a nucleic acid of the second number. INDEPENDENT CLAIMS are also included for: (1) a system (I) for assaying multiple nucleic acid molecules in...

... detecting by measuring light emission. The step of contacting the biological sample with the second number of probes further comprises labeling the probes that have *hybridized* with a nucleic acid in the sample with a detectable label. Preferred System: In (I), the nucleic acid probes comprising modified and unmodified nucleotides and...

... ability to form a base pair, where G' forms a base pair with Casterisk, and where C' forms a base pair with Gasterisk. G' is *inosine*, C' is pyrrolopyrimidine, Gasterisk is guanosine and Casterisk is *cytosine*. The number of nucleic acid probes is fixed on a substrate in an array pattern, where a sequence of a nucleic acid probe corresponds to...

... the tag is detectable by mass electrophoretic mobility or optical property. Preferred Kit: In (II), the unstructured nucleotides are selected from 2-aminoadenosine, 2-thiothymidine, *inosine* and pyrrolopyrimidine. USE - (M) or (I) is useful for assaying target nucleic acid molecules (claimed). (M) or (I) is useful for detecting, sorting, tracking and...

... molecules with reduced levels of background signal and enhanced specificity and sensitivity. (M) or (I) assays nucleic acid molecules with reduced levels of undesired cross *hybridization* and reduced levels of intramolecular secondary structure. (M) increases the multiplexing rate of assays, and the use of UNAs allows for the set of anti...

6/3,K/5 (Item 4 from file: 357)
DIALOG(R) File 357:Derwent Biotech Res.
(c) 2003 Thomson Derwent & ISI. All rts. reserv.

Novel DNA polymerases having increased activity and stability at increased pH and temperature, useful for DNA sequencing, amplification and incorporating non-natural nucleotides or nucleotide analogs - recombinant enzyme production and antibody for use in DNA repair and DNA polymorphism detection

AUTHOR: CALLEN W; MATHUR E J; SHORT J

PATENT ASSIGNEE: CALLEN W; MATHUR E J; SHORT J 2002

PATENT NUMBER: US 20020132243 PATENT DATE: 20020919 WPI ACCESSION NO.: 2003-182285 (200318)

PRIORITY APPLIC. NO.: US 948369 APPLIC. DATE: 20010906

NATIONAL APPLIC. NO.: US 948369 APPLIC. DATE: 20010906

LANGUAGE: English

...ABSTRACT: length and having an area of at least 10 contiguous nucleotides that is 50% complementary to a nucleic acid target region of (S2) and which *hybridizes* to the nucleic acid target region under moderate to highly stringent conditions to form a detectable target:probe duplex; (14) a nucleic acid probe comprising...

... and having an area of at least 15 contiguous nucleotides that is 90-97% complementary to a nucleic acid target region of (S2) and which *hybridizes* to the nucleic acid target region under moderate to highly stringent conditions to form a detectable target:probe duplex; (15) a polynucleotide probe for isolation...

... with a DNA template in PCR amplification reaction, where the template molecule is greater than 20 kb in length or contains greater than 90% guanidine-*cytosine* (GC) content. BIOTECHNOLOGY - Preparation: (I) is produced by introducing a nucleic acid encoding (I) into a host cell under conditions that allow expression of the...

... sequence and where the enzyme is able to renature and regain activity after exposure to 60-113degreesC. Preferred Nucleic Acid: An isolated nucleic acid that *hybridizes* to (I) under conditions of high, moderate or low stringency is also preferred. (I) is cDNA, genomic DNA or synthetic DNA. The sequence comparison algorithm...structural groups. Each biocatalyst reacts with many different small molecules which contain the distinct structural group. (II) is useful for sequencing a DNA molecule, by *hybridizing* a primer to a first DNA molecule, contacting the first DNA molecule with deoxyribonucleoside triphosphates (such as *inosine* dATP, dCTP, dGTP, dTTP, dITP, 7-deaza-dGTP, dUTP, (alpha-S)dATP, (alpha-S)dTTP, (alpha-S)dGTP or (alpha-S)dCTP), (II) and a...

... DNA molecule and the second primer is complementary to a sequence at or near the 3'-termini of the second strand of the DNA molecule, *hybridizing* the primer to the first strand and the second primer to the second strand in the presence of (II), under conditions such that a third...

... its analogs into a DNA molecule, by contacting a polypeptide encoded by (II) with a DNA template in a PCR amplification reaction. The nucleotides are *inosine*, 2-aminopurine or 5-*methylcytosine* (all claimed). (III) is useful in chromosome walking procedures to identify clones containing genomic sequences located adjacent to a sequence of (II). Such methods allow...

6/3,K/6 (Item 5 from file: 357)
DIALOG(R) File 357:Derwent Biotech Res.
(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0302421 DBR Accession No.: 2003-04206 PATENT

Detecting disease associated alleles, by hybridizing patient genetic material first to oligonucleotide microchips and then subjecting the resulting DNA-oligo duplex to mobile oligonucleotides - disease diagnosis using DNA chip having immobilized DNA and oligonucleotide

AUTHOR: MIRZABEKOV A D; KIRILLOV E V; PARINOV S V; BARSKI V E; DUBILEY S A
PATENT ASSIGNEE: UNIV CHICAGO 2002
PATENT NUMBER: US 6440671 PATENT DATE: 20020827 WPI ACCESSION NO.: 2002-711527 (200277)
PRIORITY APPLIC. NO.: US 498851 APPLIC. DATE: 20000207
NATIONAL APPLIC. NO.: US 498851 APPLIC. DATE: 20000207
LANGUAGE: English

...ABSTRACT: contacted with (I). BIOTECHNOLOGY - Preferred Method: GM is a DNA or RNA. The oligonucleotide molecules of O1 or O2 contain a base selected from guanine, *cytosine*, adenine, thymine or uracil, or their combinations. The oligonucleotide molecules of O1 or O2 consists of different oligonucleotide sequences and are of equal length. The...

... The substrate is a gel support. The oligonucleotides in O1 and O2 are further comprised of a universal base e.g. 5-nitroindole, 3-nitropyrrole, *inosine* or their combinations. USE - (M) is useful for detecting disease associated alleles in patient genetic material (claimed). ADVANTAGE - (M) is an efficient method for diagnosing disease by detecting multiple mutation sequences in patient DNA. The method incorporate a minimal number of oligonucleotides and utilize a minimal number of *hybridization* steps. The method is of sufficient efficiency and sensitivity so as to effectively discriminate perfect duplexes from imperfect ones. The method is more efficient in...

... is simplified. EXAMPLE - Two 8-mers located one and two bases away from a mutation site were immobilized on a microchip, and the microchip was *hybridized* to the unlabeled 19-mer. Then the duplexes formed on the microchip were *hybridized* in three more rounds with pools of two labeled 5-mers. The results showed that some *hybridized* pentamers formed perfect duplexes in a juxtaposed position to the immobilized 8-mer and extended it to a 13-bp-long duplex. The 13-base...

... or even in the terminal, position destabilized the interaction of the 5-mers much more than 8-mers. The mismatched 5-mers were either not *hybridized* at all or washed out at much lower temperature than fully complementary 5-mer. Therefore, inclusion of 5-mers provided better discrimination of perfect duplexes...

... case of terminal mismatches, The 8-mer duplexes remained stable under the washing conditions for the pentamers. The microchips sustained upto 10 rounds of successive *hybridization* with 5-mers. (35 pages)

6/3,K/7 (Item 6 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0299046 DBR Accession No.: 2003-00830 PATENT
Sequencing a nucleic acid by generating a nucleic acid containing the target sequence from a circular template and passing it through channels which allow passage of only a single strand at a time - circular template DNA for DNA sequencing or RNA sequencing

AUTHOR: SAMPSON J R
PATENT ASSIGNEE: AGILENT TECHNOLOGIES INC 2002
PATENT NUMBER: EP 1225234 PATENT DATE: 20020724 WPI ACCESSION NO.: 2002-601229 (200265)
PRIORITY APPLIC. NO.: US 262973 APPLIC. DATE: 20020116
NATIONAL APPLIC. NO.: EP 2002250379 APPLIC. DATE: 20020121
LANGUAGE: English

...ABSTRACT: of the precursors in a pair is able to form at least one base pair with another nucleotide; (c) providing an oligonucleotide primer capable of *hybridizing* to the template; (d) contacting the template, primer and precursors with an enzyme which can polymerize the precursors, so that a nucleic acid containing multiple...

...determined. BIOTECHNOLOGY - Preferred Method: The nucleic acid is DNA or RNA or an unstructured nucleic acid. The precursors are 2-aminoadenosine triphosphate, 2-thiothymidine triphosphate, *inosine* triphosphate or pyrrolopyrimidine triphosphate. The circular template is double or single stranded. The medium is an aqueous solution and electrically conductive, and a voltage is...

...with unmodified thymine, and the modified thymine is able to form a base pair with unmodified adenine. Alternatively the nucleic acid contains modified guanosine and *cytosine* unable to form base pairs, where the modified guanosine is able to form a base pair with unmodified *cytosine* and modified *cytosine* is able to form a base with unmodified guanosine. Preferably the nucleic acid contains 2-aminoadenosine, 2-thiothymidine, *inosine* and pyrrolopyrimidine. The method preferably further comprises analyzing the nucleic acids by electron tunneling. USE - M1 is used to determine the sequence of a nucleic...

6/3,K/8 (Item 7 from file: 357)

DIALOG(R) File 357:Derwent Biotech Res.

(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0297485 DBR Accession No.: 2002-19332 PATENT

Synthetic oligonucleotides complementary to a portion of the 5' untranslated region of hepatitis C virus (HCV), useful for diagnosing and treating HCV infections and hepatocellular carcinoma - antisense oligonucleotide synthesis for use in cancer gene therapy

AUTHOR: KILKUSKIE R L; FRANK B L; GOODCHILD J; WOLFE J L; ROBERTS P C; HAMLIN H A; ROBERTS N A; WALThER D M

PATENT ASSIGNEE: KILKUSKIE R L; FRANK B L; GOODCHILD J; WOLFE J L; ROBERTS P C; HAMLIN H A; ROBERTS N A; WALThER D M 2002

PATENT NUMBER: US 20020081577 PATENT DATE: 20020627 WPI ACCESSION NO.: 2002-537132 (200257)

PRIORITY APPLIC. NO.: US 887505 APPLIC. DATE: 19970702

NATIONAL APPLIC. NO.: US 887505 APPLIC. DATE: 19970702

LANGUAGE: English

...ABSTRACT: 3) a method of detecting the presence of HCV in a sample, comprising: (a) contacting the sample with the synthetic oligonucleotide; and (b) detecting the *hybridization* of the oligonucleotide to the nucleic acid; and (4) a kit for the detection of HCV in a sample comprising: (a) the synthetic oligonucleotide; and (b) a system for detecting the oligonucleotide *hybridized* with the nucleic acid. BIOTECHNOLOGY - Preferred Oligonucleotides: The synthetic oligonucleotide comprises a sequence complementary to at least 2 or 3 non-contiguous regions of an...

...sequence, selected from 40 defined sequences given in the specification. The oligonucleotide is self stabilized by a loop. At least one nucleoside is substituted by *inosine* or at least one *deoxycytosine* is substituted by 5-methyl *deoxycytosine*. The oligonucleotide is preferably selected from HCV -242, HCV 243, HCV -244 and 118 HCV-245 as given in the specification. Preparation: The oligonucleotides may...

6/3,K/9 (Item 8 from file: 357)

DIALOG(R) File 357:Derwent Biotech Res.

(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0290276 DBR Accession No.: 2002-12123 PATENT

Detecting mutations in nucleic acid, useful e.g. for diagnosing hemochromatosis, by solid phase amplification to incorporate exonuclease resistant nucleotide - DNA primer and DNA probe for polymerase chain reaction analysis to detect mutation, useful for diagnosis

AUTHOR: CAILLOUX F; GOBRON S
PATENT ASSIGNEE: NUCLEICA 2002
PATENT NUMBER: WO 200212557 PATENT DATE: 20020214 WPI ACCESSION NO.:
2002-269096 (200231)
PRIORITY APPLIC. NO.: FR 200010425 APPLIC. DATE: 20000808
NATIONAL APPLIC. NO.: WO 2001FR2574 APPLIC. DATE: 20010808
LANGUAGE: French

...ABSTRACT: one primer linked, at its 5'-end, to the supports, then DNA strands separated and strands in suspension removed by washing. Bound DNA sequences are *hybridized* to a probe (P), the 3'-end of which *hybridizes* up to, at most, position n-1, then P elongated by adding complementary nucleotides in the 5' to 3' direction, using a DNA polymerase and...
... be linked covalently, preferably of plastic and especially in the form of 96-well plates. dNTP is an alpha-S-phosphothioatedeoxynucleotide, particularly the adenosine, thymidine, *cytosine*, guanosine, uridine or *inosine* derivatives, and the enzyme used is exonuclease III. Preferred process: A third support (C), serving as negative control, is also tested. Degradation by exonuclease and...
... which primer (2) was fixed, in medium containing free primers (1), (2) and other reagents. 5'-CATGAAGTGGCTGAAGGATAA (1) 5'-GCACTCCTCTCAACCCCCA (2) Bound DNA sequences were *hybridized* to probe (3) (FITC = fluorescein isothiocyanate) and extension reaction performed in presence of either alpha-S-phosphothioatedeoxyguanosine triphosphate (X; wild type) or the corresponding adenosine...

6/3,K/10 (Item 9 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0289529 DBR Accession No.: 2002-11376 PATENT
Determining an analyte in a sample, for generating multiple double stranded nucleic acids, comprises employing a single primer sequence with a nucleobase sequence having affinity to the sequence contained in a target nucleic acid - DNA probe and DNA primer for DNA and RNA detection and synthesis
AUTHOR: ORUM H; SEEGER C
PATENT ASSIGNEE: ROCHE DIAGNOSTICS GMBH 2001
PATENT NUMBER: US 6326143 PATENT DATE: 20011204 WPI ACCESSION NO.:
2002-214947 (200227)
PRIORITY APPLIC. NO.: US 83123 APPLIC. DATE: 19980522
NATIONAL APPLIC. NO.: US 83123 APPLIC. DATE: 19980522
LANGUAGE: English

...ABSTRACT: the target nucleic acid to the analyte; (c) separating the analyte bound to the target nucleic acid from the remaining part of the sample; (d) *hybridizing* a primer to the target nucleic acid, where the primer comprises a nucleobase sequence B', and the nucleobase sequence B' *hybridizes* to the nucleobase sequence B; (e) elongating the *hybridized* primer to produce an elongation product E using the target nucleic acid as a template and using nucleotides, where at least 30 % of the nucleotides contain at least one promiscuous base which is capable of base pairing with each of adenine, guanine, *cytosine*, and thymine; (f) separating the target nucleic acid from the elongation product E; (g) *hybridizing* a further primer which comprises the nucleobase sequence B' to the elongation product E, where the elongation product E is capable of acting as a template for the elongation of the further primer; (h) elongating the *hybridized* further primer of step (g) to produce an elongation product E' using the elongation product E as a template and using nucleotides, where at least 30 % of the nucleotides contain at least one promiscuous base; (i) separating the elongation product E from the elongation product E'; (j) *hybridizing* a further primer comprising a nucleobase sequence B' to the target nucleic acid or the elongation product E; (k) elongating

the further primer of step...

... or amount of the analyte, where the lengths of the sequence I and the nucleobase sequence B are chosen such that, when the further primer *hybridizes* to the elongation product E in step (g), the further primer spans a sequence formed by elongation of the *hybridized* primer of step (e) and overlaps at least a part of the 3' region of the *hybridized* primer of step (e) by an overlap length. BIOTECHNOLOGY - Preferred Method: At least 80 %, preferably 100 % of the nucleotides in steps (e), (h) and (k) contain at least one promiscuous base. The promiscuous base is *inosine* or *deazainosine*. The nucleotides are one kind of nucleotide triphosphate. The elongation steps are accomplished by the action of at least one enzyme. The enzyme is polymerase...

... further comprises the following the step to indirectly label the elongation product E and/or elongation product E' after step (m) and before step (n): *hybridizing* the elongation product E and/or elongation product E' to a labeled nucleic acid probe and then separating *hybridized* labeled nucleic acid probe from free labeled nucleic acid probe. At least one of the nucleotides is labeled to directly label the elongation product E...

6/3,K/11 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

129199909 CA: 129(16)199909p JOURNAL

Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis

AUTHOR(S): Descamps, Diane; Calvez, Vincent; Collin, Gilles; Cecille, Agnes; Apetrei, Cristian; Damond, Florence; Katlama, Christine; Matheron, Sophie; Huraux, Jean-Marie; Brun-Vezinet, Francoise

LOCATION: Laboratoire de Virologie, Hopital Bichat-Claude Bernard, 75018, Paris, Fr.

JOURNAL: J. Clin. Microbiol. DATE: 1998 VOLUME: 36 NUMBER: 7 PAGES: 2143-2145 CODEN: JCMIDW ISSN: 0095-1137 LANGUAGE: English PUBLISHER: American Society for Microbiology

6/3,K/12 (Item 1 from file: 149)

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01070051 SUPPLIER NUMBER: 03187275 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Interferon-B-related DNA is dispersed in the human genome.

Sagar, Anurag D.; Sehgal, Pravinkumar B.; May, Lester T.; Inouye, Masayori; Slate, Doris L.; Shulman, Lester; Ruddle, Frank H.

Science, v223, p1312(4)

March 23,

1984

PUBLICATION FORMAT: Magazine/Journal ISSN: 0036-8075 LANGUAGE: English

RECORD TYPE: Fulltext TARGET AUDIENCE: Academic

WORD COUNT: 1669 LINE COUNT: 00155

... and fibroblast cells (5).

We isolated three distinct human genomic DNA clones from a human genomic DNA library in A phage Charon 4A that cross-*hybridized* with IFN-[Beta].sub.1 cDNA (4). Two of these (AB3 and AB4) are distinct from each other and from the IFN-[Beta].sub.1 gene, although they both strongly cross-*hybridized* with IFN-[Beta].sub.1 cDNA. Blot-*hybridization* tests indicated that poly(I) poly(C)-induced (I, *inosine*; C, *cytosine*) human diploid fibroblasts can contain polyadenylated RNA species 1.8, 3, 5, and 8 kb long that *hybridize* with AB3 DNA and a 12-kb species that *hybridizes* with AB4 (4). These data suggested that AB3 DNA may reside on chromosome 2

and correspond to the 1.8-kb IFN-[Beta].sub.3 mRNA. We tested this possibility with blot-*hybridization* analyses of DNA derived from a panel of human-mouse and human-hamster somatic cell hybrids; for these analyses, a 650-nucleotide DNA fragment derived from AB3 and subcloned into pBR322 (pPE-650) was used as a *hybridization* probe.

That AB3 is related to IFN-[Beta].sub.1 has been confirmed by (i) nucleic acid hybridization nsee Fig. 2 and lane 1 of...

?s inosine (s) pyrrolo pyrimidine)

>>>Unmatched parentheses

?s inosine (s) (pyrrolo pyrimidine)

32995 INOSINE

0 PYRROLO PYRIMIDINE

S7 0 INOSINE (S) (PYRROLO PYRIMIDINE)

?s inosine and (pyrrolo (w) pyrimidine)

32995 INOSINE

25296 PYRROLO

160693 PYRIMIDINE

232 PYRROLO(W) PYRIMIDINE

S8 4 INOSINE AND (PYRROLO (W) PYRIMIDINE)

?rd

...completed examining records

S9 4 RD (unique items)

?show files;ds;t/3,k/all

File 5:Biosis Previews(R) 1969-2003/Sep W2
(c) 2003 BIOSIS

File 6:NTIS 1964-2003/Sep W4

(c) 2003 NTIS, Intl Cpyrght All Rights Res

File 8:Ei Compendex(R) 1970-2003/Sep W2

(c) 2003 Elsevier Eng. Info. Inc.

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Sep W3
(c) 2003 Inst for Sci Info

File 65:Inside Conferences 1993-2003/Sep W3
(c) 2003 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2003/Sep W3
(c) 2003 Elsevier Science B.V.

File 73:EMBASE 1974-2003/Sep W3
(c) 2003 Elsevier Science B.V.

File 94:JICST-EPlus 1985-2003/Sep W3
(c) 2003 Japan Science and Tech Corp (JST)

File 98:General Sci Abs/Full-Text 1984-2003/Aug
(c) 2003 The HW Wilson Co.

File 99:Wilson Appl. Sci & Tech Abs 1983-2003/Aug
(c) 2003 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2003/Sep W3
(c) 2003 NewsRx

File 143:Biol. & Agric. Index 1983-2003/Aug
(c) 2003 The HW Wilson Co

File 144:Pascal 1973-2003/Sep W2
(c) 2003 INIST/CNRS

File 155:MEDLINE(R) 1966-2003/Sep W4
(c) format only 2003 The Dialog Corp.

File 172:EMBASE Alert 2003/Sep W3
(c) 2003 Elsevier Science B.V.

File 266:FEDRIP 2003/Aug

Comp & dist by NTIS, Intl Copyright All Rights Res

File 315:ChemEng & Biotec Abs 1970-2003/Aug
(c) 2003 DECHEMA

File 357:Derwent Biotech Res. 1982-2003/Oct W1
(c) 2003 Thomson Derwent & ISI

File 358:Current BioTech Abs 1983-2003/Aug
(c) 2003 DECHEMA

File 369:New Scientist 1994-2003/Sep W3
(c) 2003 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3
(c) 1999 AAAS

File 399:CA SEARCH(R) 1967-2003/UD=13913
(c) 2003 American Chemical Society

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 1998 Inst for Sci Info
 File 40:Enviroline(R) 1975-2003/Aug
 File 50:CAB Abstracts 1972-2003/Aug
 (c) 2003 CAB International
 File 103:Energy SciTec 1974-2003/Sep B1
 (c) 2003 Contains copyrighted material
 File 156:ToxFile 1965-2003/Sep W3
 (c) format only 2003 The Dialog Corporation
 File 162:Global Health 1983-2003/Aug
 (c) 2003 CAB International
 File 305:Analytical Abstracts 1980-2003/Sep W1
 (c) 2003 Royal Soc Chemistry
 File 35:Dissertation Abs Online 1861-2003/Aug
 (c) 2003 ProQuest Info&Learning
 File 48:SPORTDiscus 1962-2003/Sep
 (c) 2003 Sport Information Resource Centre
 File 91:MANTIS(TM) 1880-2002/Dec
 2003 (c) Action Potential
 File 149:TGG Health&Wellness DB(SM) 1976-2003/Sep W2
 (c) 2003 The Gale Group
 File 159:Cancerlit 1975-2002/Oct
 (c) format only 2002 Dialog Corporation
 File 164:Allied & Complementary Medicine 1984-2003/Sep
 (c) 2003 BLHCIS
 File 444:New England Journal of Med. 1985-2003/Sep W4
 (c) 2003 Mass. Med. Soc.
 File 467:ExtraMED(tm) 2000/Dec
 (c) 2001 Informania Ltd.

Set	Items	Description
S1	4367	INOSINE (S) GUANOSINE
S2	0	INOSINE (S) (BASE PAIR?)
S3	514	INOSINE (S) CYTOSINE
S4	0	S3 AND (BASE WITH PAIR?)
S5	13	S3 (S) HYBRIDIZ?
S6	12	RD (unique items)
S7	0	INOSINE (S) (PYRROLO PYRIMIDINE)
S8	4	INOSINE AND (PYRROLO (W) PYRIMIDINE)
S9	4	RD (unique items)

>>>KWIC option is not available in file(s): 399

9/3,K/1 (Item 1 from file: 144)
 DIALOG(R)File 144:Pascal
 (c) 2003 INIST/CNRS. All rts. reserv.

09088828 PASCAL No.: 90-0257187
9-deazapurine nucleosides. The synthesis of certain N-5- beta
-D-ribofuranosylpyrrolo(3,2-d)pyrimidines
 GIRGIS N S; ROBINS R K; COTTAM H B
 ICN nucleic acid res. inst., dep. immunochemistry, Costa Mesa CA 92626,
 USA
 Journal: Journal of heterocyclic chemistry, 1990, 27 (2) 171-175
 Language: English

... the corresponding alpha anomer, 5. Compound 4 served as the versatile intermediate from which the N-7ribofuranosyl analogs of the naturally-occurring purine nucleosides adenosine, *inosine* and guanosine were synthesized.

French Descriptors: Compose bicyclique; Heterocycle azote; Glycosylation; Glycosyle halogenure; Nucleoside; Lactame; Guanidines; Amination; Amidine ; *Pyrrolo* *Pyrimidine* derive; Ribofuranosyle(O-t-butyldimethylsilyl-5 O-isopropylidene-2,3)chlorure/ENT

9/3,K/2 (Item 2 from file: 144)

DIALOG(R)File 144:Pascal
(c) 2003 INIST/CNRS. All rts. reserv.

03042075 PASCAL No.: 81-0076573
SYNTHESE VON 7-DESAZAINOSIN DURCH PHASENTRANSFERGLYCOSIDIERUNG
(SYNTHESE DE DESAZA-7 *INOSINE* PAR GLYCOSYLATION PAR TRANSFERT DE PHASE)
SEELA F; HASSELMANN D
UNIV. PADERBORN, FACHBEREICH NATURWISS. II/PADERBORN 4790, FEDERAL
REPUBLIC OF GERMANY
Journal: CHEM. BER., 1980, 113 (10) 3389-3393
Language: GERMAN Summary Language: ENGLISH

(SYNTHESE DE DESAZA-7 *INOSINE* PAR GLYCOSYLATION PAR TRANSFERT DE PHASE)

French Descriptors: NUCLEOSIDE; REACTION CHIMIQUE; GLYCOSYLATION; GLYCOSYLE
HALOGENURE; CATALYSE TRANSFERT PHASE; DEPROTECTION; ANOMERE;
CONFIGURATION; *PYRROLO* *PYRIMIDINE* (METHOXY METHYLTHIO) -ENT;
RIBOFURANOSYLE (TRI-O-BENZYL) BROMURE-ENT; DESAZA-7INOSINE-FIN

9/3,K/3 (Item 3 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2003 INIST/CNRS. All rts. reserv.

02898947 PASCAL No.: 80-0269540
SYNTHESIS OF THE PYRROLO (3,2-D) PYRIMIDINE C-NUCLEOSIDE ISOSTERE OF
INOSINE
LIM M I; KLEIN R S; FOX J J
MEMORIAL SLOAN-KETTERING CANCER CENT., NEW YORK NY 10021, USA
Journal: TETRAHEDRON LETTERS, 1980, 21 (11) 1013-1016
Language: ENGLISH

SYNTHESIS OF THE PYRROLO (3,2-D) PYRIMIDINE C-NUCLEOSIDE ISOSTERE OF
INOSINE
OBTENTION DE DESAZA-9 *INOSINE* PAR CONVERSION D'ALCOXYCARBONYL-2 AMINO-3
PYRROLE RIBOSYLE INTERMEDIAIRE EN LE SYSTEME PYRROLO (3,2-D) PYRIMIDINE.
SPECTRES RMN SUP 1 H

French Descriptors: C-NUCLEOSIDE; REACTION CHIMIQUE; PYRROLECARBOXYLIQUE-2
ACIDE(AMINO-3 BENZYL-1 (O-ISOPROPYLIDENE-2,3 O-TRITYL-6
D-RIBOFURANOSYL)-4) ESTER ETHYLE-FIN-ENT; *PYRROLO* *PYRIMIDINE* (DIHYDRO
OXO D-RIBOFURANOSYL)-FIN; *INOSINE* ANALOGUE; FORMYCINE B ANALOGUE

9/3,K/4 (Item 4 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2003 INIST/CNRS. All rts. reserv.

02880620 PASCAL No.: 80-0152492
MASS SPECTROMETRY OF NUCLEOSIDE DERIVATIVES: SELENO ANALOGS OF PURINE AND
PYRIMIDINE BASES AND NUCLEOSIDES
LIEHR J G; WEISE C L; CRAIN P F; MILNE G H; WISE D S; TOWNSEND L B;
MCCLOSKEY J A
UNIV. UTAH, DEP. MED. CHEM., SALT LAKE CITY UT 84112, USA
Journal: J. HETEROCYCL. CHEM., 1979, 16 (6) 1263-1272
Language: ENGLISH

French Descriptors: NUCLEOSIDE PYRIMIDIQUE; SPECTRE MASSE; SCHEMA
FRAGMENTATION; SILICIUM COMPOSE ORGANIQUE; TRIMETHYLSILYLATION;
HETEROCYCLE AZOTE; CYCLE 6 CHAINONS; IMPACT ELECTRON; IONISATION CHIMIQUE
; SELENO-2URACILE-ENT; SELENO-4URACILE-ENT; *PYRROLO* *PYRIMIDINE*
(METHYLSELENO BETA -D-RIBOFURANOSYL)-ENT; SELENO-2 THYMINE(BETA
-D-RIBOFURANOSYL-1)-ENT; SELENO-6GUANOSINE(TRIMETHYLSILYL)-ENT; *INOSINE*
(METHYLSELENO-8)-ENT; SELENO-6GUANOSINE(HEXAMETHYL)-ENT

WEST[Help](#) [Logout](#) [Interrupt](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#) [Preferences](#) [Cases](#)**Search Results -**

Terms	Documents
L8 and hybrid	82

US Patents Full Text Database
US Pre-Grant Publications Full Text Database
NPG Abstracts Database
EPO Abstracts Database
Dentaltown Patents Index
IBM Technical Disclosure Bulletins

Database:**Search:**
 Search History**DATE:** Sunday, September 28, 2003 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=NO; OP=OR

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
<u>L9</u>	L8 and hybrid\$	82	<u>L9</u>
<u>L8</u>	L7 and (polymerase\$ or transcriptase\$)	89	<u>L8</u>
<u>L7</u>	inosine and 2-thiocytidine	121	<u>L7</u>
<u>L6</u>	(inosine with triphosphate) and 2-thiocytidine	1	<u>L6</u>
<u>L5</u>	2-aminoadenosine and 2-thiothymidine	23	<u>L5</u>

DB=USPT; PLUR=NO; OP=OR

<u>L4</u>	L3 and hydridiz\$	4	<u>L4</u>
<u>L3</u>	l1 and (polymerase\$ or transcriptase)	147	<u>L3</u>
<u>L2</u>	2-aminoadenosine and 2-thiothymidine and (inosine with triphosphate) and 2-thiocytidine	0	<u>L2</u>
<u>L1</u>	2-aminoadenosine or 2-thiothymidine or (inosine with triphosphate) or 2-thiocytidine	302	<u>L1</u>

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**[Terms](#)[Documents](#)

inosine and (pyrrolo with pyrimidine)

46

USPTO/PTO Full Text Database
USPTO/Created Publications Full Text Database
USPTO Abstracts Database
USPTO Abstracts Database
Patent World Patent Index
IBI Technical Disclosure Bulletins

Database:**Search:**[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Sunday, September 28, 2003 [Printable Copy](#) [Create Case](#)

Set Name Query
side by side

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=NO; OP=OR

		<u>Hit Count</u>	<u>Set Name</u>
<u>L10</u>	inosine and (pyrrolo with pyrimidine)	46	<u>L10</u>
<u>L9</u>	L8 and hybrid\$	82	<u>L9</u>
<u>L8</u>	L7 and (polymerase\$ or transcriptase\$)	89	<u>L8</u>
<u>L7</u>	inosine and 2-thiocytidine	121	<u>L7</u>
<u>L6</u>	(inosine with triphosphate) and 2-thiocytidine	1	<u>L6</u>
<u>L5</u>	2-aminoadenosine and 2-thiothymidine	23	<u>L5</u>

DB=USPT; PLUR=NO; OP=OR

<u>L4</u>	L3 and hydridiz\$	4	<u>L4</u>
<u>L3</u>	l1 and (polymerase\$ or transcriptase)	147	<u>L3</u>
<u>L2</u>	2-aminoadenosine and 2-thiothymidine and (inosine with triphosphate) and 2-thiocytidine	0	<u>L2</u>
<u>L1</u>	2-aminoadenosine or 2-thiothymidine or (inosine with triphosphate) or 2-thiocytidine	302	<u>L1</u>

END OF SEARCH HISTORY

WEST

[Generate Collection](#)[Print](#)

Search Results - Record(s) 1 through 4 of 4 returned.

 1. Document ID: US 6380368 B1

L4: Entry 1 of 4

File: USPT

Apr 30, 2002

US-PAT-NO: 6380368

DOCUMENT-IDENTIFIER: US 6380368 B1

TITLE: Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

 2. Document ID: US 6287772 B1

L4: Entry 2 of 4

File: USPT

Sep 11, 2001

US-PAT-NO: 6287772

DOCUMENT-IDENTIFIER: US 6287772 B1

TITLE: Methods, kits and compositions for detecting and quantitating target sequences

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

 3. Document ID: US 5914396 A

L4: Entry 3 of 4

File: USPT

Jun 22, 1999

US-PAT-NO: 5914396

DOCUMENT-IDENTIFIER: US 5914396 A

** See image for Certificate of Correction **

TITLE: 2'-O-modified nucleosides and phosphoramidites

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

 4. Document ID: US 5830653 A

L4: Entry 4 of 4

File: USPT

Nov 3, 1998

US-PAT-NO: 5830653

DOCUMENT-IDENTIFIER: US 5830653 A

TITLE: Methods of using oligomers containing modified pyrimidines

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draft Desc	Image										

[Generate Collection](#)[Print](#)

Terms	Documents
L3 and hydridiz\$	4

Display Format: [TI](#) [Change Format](#)[Previous Page](#) [Next Page](#)